http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101626681-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 |
| filingDate | 2012-05-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101626681-B1 |
| titleOfInvention | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| abstract | The present invention relates to compounds of the general formula (I) and pharmaceutically acceptable salts thereof, to processes for their preparation, to intermediates used in their preparation and to compositions containing such compounds and to methods of treatment of central nervous system disorders, cognitive disorders, schizophrenia , Dementia, and other disorders. The present invention relates to the use of such compounds as a method for the treatment of diseases or conditions selected from the group consisting of: (I) . The present invention further provides a compound of formula (Id) as a CYP3A4 selective inhibitor and a pharmaceutically acceptable salt thereof: (Id) . |
| priorityDate | 2011-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 729.